Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.55 |
| ▸ | TTK | P33981 | 2/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.55 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.55 |
| ▸ | ITK | Q08881 | 2/20 | 0.52 |
| ▸ | WDR5 | P61964 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13863966 | 0.89 | AURKA (0.56) | CYP1A2CYP2C18CYP2C19KCNH2HDAC1 | |
| SCHEMBL8077870 | 0.89 | CYP1A2 (0.76) | CYP1A2CYP2C18CYP2C19KCNH2HDAC1 | |
| SCHEMBL20181478 | 0.85 | HDAC2 (0.67) | CYP1A2CYP2C18CYP2C19KCNH2HDAC1 | |
| SCHEMBL4579757 | 0.83 | HDAC1 (0.64) | KCNH2HDAC1HDAC2HDAC3 | |
| SCHEMBL4580967 | 0.80 | HDAC2 (0.59) | CYP1A2CYP2C18CYP2C19KCNH2HDAC1 | |
| SCHEMBL4580962 | 0.80 | HDAC2 (0.59) | CYP1A2CYP2C18CYP2C19KCNH2HDAC1 | |
| SCHEMBL4580002 | 0.78 | HDAC1 (0.60) | CYP1A2CYP2C18CYP2C19KCNH2HDAC1 | |
| SCHEMBL4580000 | 0.78 | HDAC1 (0.60) | CYP1A2CYP2C18CYP2C19KCNH2HDAC1 | |
| SCHEMBL4581337 | 0.78 | HDAC2 (0.74) | CYP1A2CYP2C18CYP2C19KCNH2HDAC1 | |
| SCHEMBL4579014 | 0.78 | HDAC1 (0.67) | KCNH2HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124631-A1 | Combination Therapy | METHYLGENE, INC. (CA) | 2009-05-14 | — | — | US | disclosed |
| US-20090124631-A1 | Combination Therapy | METHYLGENE, INC. (CA) | 2009-05-14 | — | — | US | disclosed |
| WO-2009033281-A1 | CANCER COMBINATION THERAPY WITH A SELECTIVE INHIBITOR OF HISTONE DEACETYLASE HDAC1, HDAC2 AND/OR HDAC3 AND A MICROTUBULE STABILIZER | METHYLGENE INC. (CA) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124631-A1 | Combination Therapy | HDAC6, HDAC1, HDAC2 | CYP1A2 4317/4885CYP2C18 4439/4885CYP2C19 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.